CJC-1295 with DAC vs no DAC: what the extra piece changes, and why it matters when you read forum claims

In public posts, people describe the DAC and no-DAC versions of “CJC-1295” as effectively different peptides with different half-lives, and they disagree about which is preferable. They are right that the two differ, because the name covers two different molecules: CJC-1295 with DAC and CJC-1295 without DAC. This page explains what DAC is, what it changes in the body, what the research behind each form actually measured, and how to read a forum claim once you know which molecule it is about. For the broader picture, see the hub overview of CJC-1295, our guide to what CJC-1295 and ipamorelin actually do, and the head-to-head of CJC-1295 vs ipamorelin.

What is CJC-1295?

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), the signal the hypothalamus sends to tell the pituitary gland to release growth hormone (GH). Its developer, ConjuChem, described it as a modified copy of the first 29 amino acids of human GHRH, the active fragment, with four substitutions plus an added lysine carrying a reactive group that latches onto albumin in the blood (Jetté et al., 2005). That albumin-binding add-on is the “drug affinity complex,” or DAC. A 2026 endocrinology review notes that the four substitutions make the peptide more resistant to breakdown, and that two variants now circulate in the off-label market: one with DAC and one without (Dominikowski et al., 2026). The no-DAC version is the one usually labeled “mod GRF 1-29.”

What does CJC-1295 do?

CJC-1295 prompts the pituitary to release more of the body’s own GH, which in turn raises IGF-1. In healthy adults, a single injection of the DAC form raised mean GH 2- to 10-fold for six days or more and IGF-1 1.5- to 3-fold for 9 to 11 days (Teichman et al., 2006). That hormone rise is what has been shown. Whether either form builds muscle, cuts fat or improves performance has not been shown in any published human trial (Dominikowski et al., 2026).

What does DAC actually change in the body?

DAC changes how long the molecule survives, and almost everything else follows from that. Native GHRH is broken down fast: in human plasma an enzyme snips off its first two amino acids, leaving a fragment with less than a thousandth of the original activity, and after an intravenous dose its half-life was 6.8 minutes (Frohman et al., 1986). ConjuChem’s chemists attached the DAC so the peptide would bind albumin in the blood and ride along with it. In rats, the DAC version showed up bound to albumin 15 minutes after injection, stayed in circulation beyond 24 hours, and was detectable in plasma beyond 72 hours (Jetté et al., 2005). In people, the estimated half-life was 5.8 to 8.1 days (Teichman et al., 2006).

The no-DAC form keeps the four protective substitutions but drops the albumin anchor. No published human study has reported its half-life; the 2026 review lists it as “not reported in human studies” (Dominikowski et al., 2026). So the honest description is “shorter-acting than the DAC form, exact figure unmeasured in people,” not a specific number of minutes.

CJC-1295 with DAC vs no DAC, side by side

The table lines up the two forms, with native GHRH as a reference point. Read it as a map of what is and is not known, not as a recommendation for either form.

CJC-1295 with DAC, CJC-1295 without DAC and native GHRH. Half-life figures come only from the cited pharmacokinetic studies; ’not measured’ means no published human study has reported one.

Attribute	CJC-1295 with DAC	CJC-1295 without DAC (mod GRF 1-29)	Native GHRH (reference)
What it is	Modified GHRH(1-29) plus an albumin-binding lysine group	Modified GHRH(1-29) without the albumin-binding group	The body’s own releasing hormone
Binds albumin in blood	Yes	No	No
Human half-life	5.8 to 8.1 days (Teichman 2006)	Not measured in any published human study	6.8 minutes after IV injection (Frohman 1986)
Effect on GH pattern in people	One week after injection: trough GH up 7.5-fold, pulses preserved	Not measured in people	Short-term infusions enhance GH pulses (background in Ionescu 2006)
Published human studies	Phase I placebo-controlled trials in healthy adults	None	Pharmacokinetic studies (e.g. Frohman 1986)
Evidence tier in the 2026 review	B: phase I studies, no controlled efficacy data	D: no peer-reviewed human studies	Not graded
Human muscle or fat-loss trials	No	No	No

What does the research show for each form?

For the DAC form, the evidence level is small human pharmacology trials. Two randomized, placebo-controlled, double-blind trials in healthy adults aged 21 to 61, lasting 28 and 49 days, measured GH and IGF-1; IGF-1 stayed above baseline for up to 28 days after repeated doses, and the authors saw “evidence of a cumulative effect” (Teichman et al., 2006). A companion study in healthy men aged 20 to 40 sampled blood every 20 minutes overnight, one week after a single injection (Ionescu & Frohman, 2006). Animal work adds detail: in mice bred without their own GHRH, daily CJC-1295 restored normal body weight and length, while the same dose every two or three days did not fully normalize growth, a reminder that “lasts a week in the blood” and “a week of full effect” are not the same claim (Alba et al., 2006). PeptideAgent’s CJC-1295 profile collects the same two trials with their sources and gives a half-life of 5.8 to 8.1 days for the albumin-binding version.

For the no-DAC form, the evidence level is no human studies at all. The 2026 review states that “CJC-1295 without DAC” remains “essentially uncharacterised in the peer-reviewed human literature” and that claims about natural pulses or body composition come largely from extrapolating from a related compound, GHRH(1-29), known as sermorelin, and from non-academic sources (Dominikowski et al., 2026). The review places it in its lowest tier, alongside compounds supported only by preclinical extrapolation and user narratives. Neither form has a human trial measuring muscle, strength or fat loss.

Does CJC-1295 with DAC stop natural growth hormone pulses?

Not in the one study that measured it. A frequent forum claim is that DAC causes a constant “GH bleed” that flattens the body’s natural rhythm. When researchers checked, GH pulses kept the same frequency and size after a DAC injection; what changed was the floor between pulses, with trough GH up 7.5-fold, mean GH up 46% and IGF-1 up 45% (Ionescu & Frohman, 2006). So the half-truth in the claim is that DAC does keep GH elevated between pulses; the part that does not hold up is that pulses disappear. That was a single study of one-week effects, so it does not settle what months of use would do.

Do the side effects differ between DAC and no DAC?

Nobody knows for the no-DAC form, because no human safety data exist for it. For the DAC form, the short trials reported “no serious adverse reactions” and called it “safe and relatively well tolerated” at the doses tested (Teichman et al., 2006). Across GH-axis peptides as a class, the 2026 review lists reported effects including blood sugar disturbances, fluid retention, muscle and joint pain and injection-site reactions, and it flags long-term IGF-1 elevation as the central long-term concern (Dominikowski et al., 2026).

The form matters to the mechanism, which is why forum worries split along DAC lines. A molecule that keeps baseline GH raised for days sits closer to the physiology of chronic GH excess, and in acromegaly, the condition defined by too much GH, “the principal mediator of insulin resistance” is GH hypersecretion (Clemmons, 2002). That is a biologically reasonable concern, not a measured outcome in CJC-1295 users. Our guide to GH peptide side effects and realistic expectations covers the class in more depth.

Which form is in a CJC-1295 and ipamorelin blend?

It depends on the product, and labels do not always say. The 2026 review describes the fitness-community stack as ipamorelin paired with CJC-1295 “typically the non-DAC form,” and calls the practice “largely driven by anecdotal rationale” with limited controlled evidence for synergy or body-composition results (Dominikowski et al., 2026). The logic is that the two act on different receptors: CJC-1295 on the GHRH receptor and ipamorelin on the ghrelin receptor (Dominikowski et al., 2026). Ipamorelin itself is short-acting, with a terminal half-life of about two hours after an intravenous infusion in healthy men (Gobburu et al., 1999). If a blend’s listing does not name the form, the honest reading is “form not stated,” and the evidence you can attach to it is correspondingly thinner.

Why does “CJC-1295” pricing look so inconsistent?

Partly because two listings with the same name may not be the same molecule. There is no approved CJC-1295 product to anchor a reference price, so prices are set by whoever sells it, and the DAC and no-DAC forms are marketed under one name. A Norwegian doping-control lab found that an unknown preparation submitted at the request of police and customs contained a 29-amino-acid peptide with a sequence consistent with a product “marketed under the name CJC-1295” (Henninge et al., 2010). The DAC molecule its developer described is that 29-amino-acid backbone plus an extra lysine carrying the albumin-binding group (Jetté et al., 2005), so that preparation fits the no-DAC description, although the paper itself does not use that label. When comparing costs, compare the form first. In community posts, some users say they favor the DAC form partly for lower cost.

What are people saying about DAC vs no DAC?

In public posts, people treat the two forms as different peptides, which matches the pharmacology, and they disagree about which is better. Our Community Insights summary of 17 public posts on X about CJC-1295, from July 13 to 19, 2026, found these themes; they are anecdotes, not evidence:

• Convenience and cost. Some posters favor the DAC version for less frequent injections and lower cost.
• Pulses vs a steady signal. Others warn that DAC keeps GH raised continuously rather than in natural pulses, and link that to insulin resistance and joint pain. The pulse half of that worry is not what the one human study found; the “raised between pulses” half is.
• Side effects. Reports include intense flushing early on, and one user said CJC-1295 disrupted their sleep and left them exhausted, which they said tesamorelin did not.
• Where it ranks. One shared tier list put CJC-1295 below GH itself and tesamorelin; one user said CJC-1295 wins on cost.

The full summary lives on the hub’s CJC-1295 community page.

How should you read a forum claim about CJC-1295?

Start by asking which molecule the claim is about, because a claim about one form often borrows evidence from the other. If someone cites a human trial, it was the DAC form (Teichman et al., 2006); if they are describing a short-acting “natural pulse” protocol, they are most likely describing the no-DAC form, for which no human data exist (Dominikowski et al., 2026). Next, check whether the claim is about a hormone level or an outcome: rising GH and IGF-1 are documented for the DAC form; muscle gain and fat loss are not documented for either. Finally, check whether the “evidence” is a mouse study, a hormone assay in a small group of volunteers, or a person’s report, and weigh it accordingly.

So, DAC or no DAC?

The evidence cannot pick a winner for physique, because neither form has been tested for it. What it can tell you is what each one is. The DAC form is a long-lived GHRH analog with small human trials showing days of raised GH and IGF-1 and preserved pulses over one week. The no-DAC form is shorter-acting and, in the peer-reviewed human literature, essentially unstudied. If you see “CJC-1295” in a thread, a study or a product listing, find out which one it means before deciding what the claim is worth, ideally with a clinician who can look at your labs. For the stack question, see CJC-1295 vs ipamorelin.

Status: CJC-1295 is not FDA-approved; sold by some telehealth providers as a compounded prescription. What this status means.

Educational information only, not medical advice. Every efficacy and safety statement on this page is sourced to the peer-reviewed literature linked above; the community summary reflects public posts on X analyzed in July 2026. Updated October 12, 2026. This page is drafted with AI assistance and fact-checked against the cited primary sources before publication.